{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:15:22Z","timestamp":1790010922519,"version":"4.0.1"},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The utility of ambulatory blood pressure monitoring (ABPM) among patients with various forms of autonomic dysfunction (AD) is unknown. Twenty-four-hour ABPM among patients with postural orthostatic tachycardia syndrome (POTS), AD without POTS, and control patients without AD were compared. Patients with AD without POTS had high rates of uncontrolled blood pressure (76%), whereas 19% of patients with POTS had uncontrolled blood pressure, suggesting ABPM may provide less value among patients with POTS.<\/jats:p>","DOI":"10.1038\/s41371-025-01031-7","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:07:52Z","timestamp":1748578072000},"page":"534-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of ambulatory blood pressure monitoring among patients with postural orthostatic tachycardia syndrome, autonomic dysfunction, and controls"],"prefix":"10.1038","volume":"39","author":[{"given":"Megan","family":"Bach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kassab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-1539","authenticated-orcid":false,"given":"Ahmed","family":"Mohamed Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandan","family":"Kodur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3262-792X","authenticated-orcid":false,"given":"Luke J.","family":"Laffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"1031_CR1","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jacc.2018.12.064","volume":"73","author":"JJ Goldberger","year":"2019","unstructured":"Goldberger JJ, Arora R, Buckley U, Shivkumar K. Autonomic nervous system dysfunction: JACC focus seminar. J Am Coll Cardiol. 2019;73:1189\u2013206.","journal-title":"J Am Coll Cardiol"},{"key":"1031_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jacc.2018.11.059","volume":"73","author":"M Bryarly","year":"2019","unstructured":"Bryarly M, Phillips LT, Fu Q, Vernino S, Levine BD. Postural orthostatic tachycardia syndrome: JACC focus seminar. JACC. 2019;73:1207\u201328.","journal-title":"JACC"},{"key":"1031_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10286-018-0529-8","volume":"28","author":"A Fanciulli","year":"2018","unstructured":"Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28:355\u201362.","journal-title":"Clin Auton Res"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01031-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01031-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:46:05Z","timestamp":1757148365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-025-01031-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":3,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1038\/s41371-025-01031-7","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest related to this manuscript. Dr. Laffin has been a consultant and\/or served on steering committees for AstraZeneca, Crispr Therapeutics, Eli Lilly, Idorsia, Kardigan, Medtronic, Mineralys Therapeutics, Novo Nordisk, Recor, Ripple Medical, and Stability Health; has received research funding from AstraZeneca. The other authors have no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}